News
02-06-2011, 11:23 PM
EpiCept Corporation today announced positive results from a Phase IIb trial evaluating the efficacy and safety of EpiCept NP-1 in chemotherapy-induced peripheral neuropathy. EpiCept NP-1 is a topical analgesic cream containing two FDA-approved drugs, amitriptyline and ketamine, in development for the relief of pain from various peripheral neuropathies.
More... (http://www.news-medical.net/news/20110207/Positive-results-from-EpiCept-NP-1-Phase-IIb-trial-in-patients-with-CPN.aspx)
More... (http://www.news-medical.net/news/20110207/Positive-results-from-EpiCept-NP-1-Phase-IIb-trial-in-patients-with-CPN.aspx)